{"public_id":"cl_d3cc3153d55760aabc79d67c4bf5daa1","status":"active","superseded_by_public_id":null,"corpus_id":275406579,"text":"Non-steroidal anti-inflammatory drugs remain first-line pharmacotherapy, while tumour necrosis factor, IL-17, and Janus kinase inhibitors are considered second-line therapies.","confidence":0.98,"paper":{"corpus_id":275406579,"title":"Axial spondyloarthritis.","url":"https://sah.borca.ai/papers/275406579"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_2a60f9b4b388a4e9e1eca4e5916359e5","name":"tumour necrosis factor inhibitors","description":"Biologic drugs that block tumour necrosis factor signaling.","types":["drug class"],"url":"https://sah.borca.ai/concepts/co_2a60f9b4b388a4e9e1eca4e5916359e5"},{"public_id":"co_74534dc8876e762d02f9745639045099","name":"IL-17 inhibitors","description":"Drugs that inhibit interleukin-17 signaling.","types":["drug class"],"url":"https://sah.borca.ai/concepts/co_74534dc8876e762d02f9745639045099"},{"public_id":"co_82145aaa71e91602d5aa1c6776374ab2","name":"non-steroidal anti-inflammatory drugs","description":"Anti-inflammatory medications used as first-line pharmacotherapy.","types":["drug class"],"url":"https://sah.borca.ai/concepts/co_82145aaa71e91602d5aa1c6776374ab2"},{"public_id":"co_8b9a7ec628ffffcaae9804078935bb2b","name":"Janus kinase inhibitors","description":"Drugs that inhibit Janus kinase signaling pathways.","types":["drug class"],"url":"https://sah.borca.ai/concepts/co_8b9a7ec628ffffcaae9804078935bb2b"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_d3cc3153d55760aabc79d67c4bf5daa1"}